Results 131 to 140 of about 6,651,279 (337)

Mental health needs, stressors and coping resources of internally displaced children in post-conflict Syria: A qualitative study with NGO staff

open access: yesCambridge Prisms: Global Mental Health
Although the needs of conflict-affected children are well-documented, research on the post-conflict period is limited, particularly in Syria, where the fall of the Assad regime has created a rapidly evolving environment for internally displaced children.
Betül Çakır-Mete   +2 more
doaj   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

open access: yesMolecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak   +8 more
wiley   +1 more source

Adolescent mental health in post-conflict communities: results from a cross-sectional survey in Northern Uganda. [PDF]

open access: yesConfl Health, 2023
Wipfli H   +5 more
europepmc   +2 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

open access: yesMolecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié   +16 more
wiley   +1 more source

Emergency care in post-conflict settings: a systematic literature review. [PDF]

open access: yesBMC Emerg Med, 2023
Werner K, Kak M, Herbst CH, Lin TK.
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Introduction: ‘Moving On’? Official Responses to Mass Harm and the Question of Justice

open access: yesOñati Socio-Legal Series, 2017
How are claims to justice formulated, invoked and confronted in relation to reports of mass human suffering? What notions of justice inform the scope and nature of official inquiries into harms and the responsiveness of governments to their findings and ...
Jennifer Balint   +3 more
doaj  

Remittance flows to post-conflict states: perspectives on human security and development [PDF]

open access: yes, 2013
This repository item contains a single issue of the Pardee Center Task Force Reports, a publication series that began publishing in 2009 by the Boston University Frederick S.
Feeley, Frank   +13 more
core   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy